Can cross-border deals behind Chinese biotech’s profitable first half last?
- Posted on August 25, 2026
- By South China Morning Post
- 1 Views
- 1 min read
In brief
Generating AI summary…
Can cross-border deals behind Chinese biotech’s profitable first half last?
Out-licensing deals have overtaken IPOs as the primary lifeline for cash-starved Chinese drug makers, analysts say.
